Long-term efficacy of capecitabine plus oxaliplatin chemotherapy on stage III colon cancer: A meta-analysis

Figure 1 Flow chart of the 12 articles that met the inclusion criteria.

Figure 2 The combined analysis. A: The capecitabine plus oxaliplatin (XELOX) group had longer overall survival compared with other chemotherapy groups; B: The XELOX group had longer disease-free survival compared with other chemotherapy groups.

Figure 3 Results of the overall survival subgroup analysis (subgroup analysis of different follow-up visits).

Figure 4 Subgroup analysis of overall survival and disease-free survival [capecitabine plus oxaliplatin (XELOX) vs other chemotherapy groups]. A: The capecitabine plus oxaliplatin (XELOX) group had longer overall survival compared with other chemotherapy groups; B: The XELOX group had longer disease-free survival compared with other chemotherapy groups.

Figure 5 Process of deflection analysis. A: Overall survival (The capecitabine plus oxaliplatin (XELOX) group vs other chemotherapy groups); B: Disease-free survival (The XELOX group vs other chemotherapy groups); C: Subgroup analysis of disease-free survival (The XELOX group vs other chemotherapy groups).